Table 1. Patients' characteristics at enrolment of the study.

ATG treatment*	Sex †	Age [years]	CRP [mg/dl]♣	Leukocytes [G/l]♦	Hb [g/l]	concommitant immune-suppressive therapy‡	TX-organ	treated condition
N	M	56	0.7	9.2	158	CsA, MMF, GC, aIL2R	L	chronic emphysema
N	M	57	2.3	5.0	108	CsA, GC, MMF	K	chronic GN
N	M	46	0.7	4.6	126	aIL2R, FK-506, GC	L	CirrhHep
N	M	43	0.7	8.3	117	aIL2R, FK-506, GC	K	chronic GN
N	M	61	0.7	2.9	100	aIL2R, FK-506, GC	L	CirrhHep
N	F	50	3.5	4.8	100	aIL2R, RAP, MMF, GC	K	PN
N	M	44	0.7	4.4	162	CsA, GC, MMF	K	Alport syndrome
N	M	45	0.7	10.6	136	FK-506, GC, MMF	K	chronic graft rejection
N	F	59	0.4	9.0	129	aIL2R, FK-506, MMF,GC	K	PN
N	M	44	0.3	9.3	129	FK-506, MMF, GC	K	IgA nephropathy
N	M	51	0.3	3.8	142	FK-778, FK-506, GC	L	CirrhHep
Y	M	51	0.7	4.7	133	ATG, FK-506, RAP, GC	K, P	DM I
Y	F	48	0.7	6.6	108	ATG, FK-506, RAP, GC	K, P	DM I
Y	F	29	0.3	8.0	105	ATG, FK-506, MMF, GC	K, P	DM I
Y	F	24	0.4	7.9	112	ATG FK-506, RAP, GC	K, P	DM I
Y	M	41	0.5	7.1	155	ATG, FK-506, MMF, GC	K, P	DM II

^*no, N; yes, Y;

^†male, M; female, F;

^♣C-reactive protein ,CRP (normal values: 0–0.6 mg/dl);

^♦normal values: 3.8–10.5 G/l; hemoglobin, Hb (normal values: 120–157 g/l).

^‡cyclosporine A, CsA; mycophenolate mofetil, MMF; glucocorticoids, GC; monoclonal anti-human IL-2 receptor antibodies (daclizumab, zenapax™), aIL2R; tacrolimus, FK-506; rapamycine, RAP; monoclonal anti-human CD52 antibodies (alemtuzumab, campath™), anti-CD52 Ab; leflunomide analogue FKK-778, FKK-778; ATG Fresenius, ATG.

Decompensated cirrhosis hepatis, CirrhHep; diabetes mellitus with nephropathy, DM; glomerulonephritis, GN; Kidney, K; lung, L; pancreas, P; polycystic nephropathy, PC; transplant, TX.